Paper Details

  1. Home
  2. Paper Details

Pitavastatin therapy in polymedicated patients is associated with a low risk of drug-drug interactions: analysis of real-world and phase 3 clinical trial data.

Author: GoshoMasahiko, HounslowNeil, TanahashiMasaya, TeramotoTamio

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Pitavastatin is a statin that has a reduced potential for drug-drug interactions. This post hoc analysis of two large datasets suggests that pitavastatin is associated with a low incidence of adverse events, including myalgia, when coadministered with other medications.
Paper Details　
Original Abstract of the Article :
Medications that interact with the pathways responsible for statin metabolism may increase the risk of statin-associated myalgia. Pharmacokinetic studies show that pitavastatin is carried into the liver by a range of transporters and is minimally metabolized by cytochrome P450 in healthy volunteers,...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.5414/CP202195

データ提供：米国国立医学図書館（NLM）

Pitavastatin: Low Risk of Drug-Drug Interactions

This research investigates the potential for drug-drug interactions (DDIs) associated with pitavastatin, a statin medication used to lower cholesterol levels. It's like exploring a vast desert landscape, seeking to understand the intricate interactions between different medications. The researchers analyzed real-world and clinical trial data to assess the incidence of adverse events in patients taking pitavastatin with other medications. They observed a low risk of DDIs, suggesting that pitavastatin may be a safer option for polymedicated patients. This finding is significant because it may allow clinicians to prescribe pitavastatin with greater confidence.

Pitavastatin: A Potentially Safer Statin Option

This research provides evidence supporting the use of pitavastatin as a potentially safer statin option for polymedicated patients. The study found a low risk of DDIs associated with pitavastatin, making it a valuable alternative for patients taking multiple medications. It's like finding a safe and navigable path in a desert landscape filled with potential hazards.

Health Impact and Application in Daily Life

This research highlights the importance of considering DDIs when prescribing medications. While pitavastatin appears to carry a lower risk of DDIs, it's crucial to consult with a healthcare provider to ensure optimal medication management. This is like navigating a desert – it's important to have a reliable guide to avoid potential pitfalls.

Dr.Camel's Conclusion

This research sheds light on the intricate interactions between medications, making it a valuable guide for navigating the desert of drug interactions. Pitavastatin emerges as a potential oasis in this landscape, offering a safer option for patients taking multiple medications. It's a reminder that even in a complex desert, careful planning and research can lead to a smoother journey.

Date :
  1. Date Completed 2015-10-26
  2. Date Revised 2015-07-28
Further Info :

Pubmed ID

26104032

DOI: Digital Object Identifier

10.5414/CP202195

Related Literature

Article Analysis
・Side Effects of pitavastatin
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.